caa a22 4500 445331372 CHVBK 20180317142738.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10689-011-9423-4 doi (NATIONALLICENCE)springer-10.1007/s10689-011-9423-4 Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study [Elektronische Daten] [Kui Huang, Lia Gutierrez, Steffen Bülow, Steven Gallinger, Antoni Castells, Craig Eagle, James Church] Familial adenomatous polyposis (FAP) is a rare genetic disease. Without treatment, FAP patients have a 100% lifetime risk of developing colorectal cancer. This study was conducted to evaluate the effect of celecoxib treatment in prolonging the time to FAP-related events and to document the safety profile of the long-term use of celecoxib (≥6months) in FAP patients. FAP patients receiving celecoxib in routine clinical practice were individually matched with historical/concurrent FAP patients not receiving celecoxib. The study population included patients aged 12years or older registered in national and regional FAP registries in Denmark, the United States, Spain, and Canada. Descriptive statistics were used to summarize dose and duration among celecoxib treated patients. The primary study endpoints, time-to-next-FAP events, were examined with Kaplan-Meier method. Fifty four celecoxib-treated patients were recruited and a matched control was identified for 13 of these patients. The Kaplan-Meier estimated probability of not having a polypectomy 12 and 60months post- ileorectal anastomosis in the celecoxib-treated patients (n=33) was 60.6% and 42.2%, respectively. The estimated probability of not having a polypectomy 6-60months post-ileal pouch-anal anastomosis the celecoxib-treated patients (n=24) was 100%. The median total daily dose of celecoxib was 698.9mg with the majority treated more than 24months. Five celecoxib-treated patients experienced 6 serious adverse events with one of these events (rash) considered related to celecoxib. Long term celecoxib treatment appeared to be well tolerated in FAP patients with or without FAP-related surgeries. Springer Science+Business Media B.V., 2011 Familial adenomatous polyposis nationallicence Ileo-rectal anastomosis nationallicence Ileal pouch-anal anastomosis nationallicence Celecoxib nationallicence Desmoid tumor nationallicence Excisional polypectomy nationallicence Huang Kui Pfizer Inc, New York, NY, USA aut Gutierrez Lia RTI Health Solutions, Epidemiology, Barcelona, Spain aut Bülow Steffen The Danish Polyposis Register, Hvidovre University Hospital, Copenhagen, Denmark aut Gallinger Steven Samuel Lunenfeld Research Institute, Toronto General Hospital, Toronto, ON, Canada aut Castells Antoni Department of Gastroenterology, Hospital Clínic, Barcelona, Catalonia, Spain aut Eagle Craig Pfizer Inc, New York, NY, USA aut Church James Department of Colorectal Surgery, Digestive Diseases Institute, Cleveland Clinic Foundation, Cleveland, OH, USA aut Familial Cancer Springer Netherlands 10/2(2011-06-01), 303-308 1389-9600 10:2<303 2011 10 10689 https://doi.org/10.1007/s10689-011-9423-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10689-011-9423-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Huang Kui Pfizer Inc, New York, NY, USA aut NATIONALLICENCE 700 1- Gutierrez Lia RTI Health Solutions, Epidemiology, Barcelona, Spain aut NATIONALLICENCE 700 1- Bülow Steffen The Danish Polyposis Register, Hvidovre University Hospital, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Gallinger Steven Samuel Lunenfeld Research Institute, Toronto General Hospital, Toronto, ON, Canada aut NATIONALLICENCE 700 1- Castells Antoni Department of Gastroenterology, Hospital Clínic, Barcelona, Catalonia, Spain aut NATIONALLICENCE 700 1- Eagle Craig Pfizer Inc, New York, NY, USA aut NATIONALLICENCE 700 1- Church James Department of Colorectal Surgery, Digestive Diseases Institute, Cleveland Clinic Foundation, Cleveland, OH, USA aut NATIONALLICENCE 773 0- Familial Cancer Springer Netherlands 10/2(2011-06-01), 303-308 1389-9600 10:2<303 2011 10 10689 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer